Navigation Links
Champalimaud Foundation Unveils C-TRACER in Hyderabad, India
Date:1/29/2008

Center to Utilize Stem Cells in Fight Against Blindness

HYDERABAD, India, Jan. 29 /PRNewswire/ -- The Champalimaud Foundation, one of the largest scientific foundations in the European Union, has announced the inauguration of the Champalimaud Center of Translational Eye Research (C-TRACER). The official ceremony will be January 30, 2008 in Hyderabad, India, and will attended by some of the most recognized vision experts and practitioners from Australia, India, the EU, and the U.S., as well as patients who have had their vision restored by the techniques that C-TRACER will utilize throughout the developing world.

C-TRACER is the result of an historic agreement between the Champalimaud Foundation and the LV Prasad Eye Institute (LVPEI), one of the foremost translational vision research centers in the world. One of only three places in the world which utilizes such techniques, the Institute uses stem cell science in the treatment of blindness, a cutting-edge technique that enables eye doctors to take cells from living adults and use them to grow the outer part of corneas. In one of the most revolutionary procedures in medical science today, doctors at the Institute have also begun using stem cells from the lip to produce corneas for implantation into the blind patient to restore sight.

C-TRACER will focus on the following areas: Research and therapy through the utilization of stem cells in vision-related illnesses; translational research utilizing existing and novel clinical methodologies, with the objective of furthering the knowledge of vision in such a way that it can be readily applied to the patient; exchange programs involving scientists chosen by the LVPEI and the Champalimaud Foundation; and, introduction of "capacity building" programs within Lusophone and other developing countries. In this way, C-TRACER will export the scientific model, thereby demonstrating a major goal of the program: to give new hope to the millions of blind people in the world today.

"With C-TRACER, the Champalimaud Foundation demonstrates its commitment to narrowing the gap between medical and scientific research and its practical applications," said Leonor Beleza, president of the Champalimaud Foundation. "This partnership with the LVPEI is a major step in the quest to eradicate world blindness through multilateral collaboration with some of the world's most prominent researchers and practitioners."

About the Champalimaud Foundation

The Champalimaud Foundation was created in 2004 at the bequest of the late Portuguese industrialist and entrepreneur Antonio de Sommer Champalimaud. With a 500 million endowment, it is one of the largest private foundations in Europe devoted to science. The Foundation is committed to supporting cutting- edge developments in medical science in the fields of vision, neuroscience, and oncology.

NOTE: High-resolution photos, B-Roll, and access to physicians and patients are available upon request.


'/>"/>
SOURCE The Champalimaud Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
5. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
6. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
7. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
8. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
9. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):